Trial Profile
A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Valbenazine (Primary)
- Indications Drug-induced dyskinesia
- Focus Adverse reactions; Registrational
- Acronyms Kinect 4
- Sponsors Neurocrine Biosciences
- 30 Aug 2023 Results published in the Neurocrine Biosciences Media Release.
- 29 Aug 2023 According to an Neurocrine Biosciences media release, findings from a data analysis of this study were presented at the MDS International Congress of Parkinson's Disease and Movement Disorders in Copenhagen, Denmark.
- 29 Aug 2023 Results presented in the Neurocrine Biosciences Media Release.